Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

62.71
-0.9800-1.54%
Post-market: 63.951.24+1.98%19:55 EDT
Volume:1.57M
Turnover:98.64M
Market Cap:12.02B
PE:28.41
High:63.62
Open:63.20
Low:62.20
Close:63.69
Loading ...

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Zacks
·
10 Apr

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Zacks
·
10 Apr

Viatris to Pay $335 Million for Settlement of Opioid-Related Claims

Zacks
·
08 Apr

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

Zacks
·
08 Apr

What Makes BioMarin (BMRN) a New Buy Stock

Zacks
·
08 Apr

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks
·
07 Apr

RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
05 Apr

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Zacks
·
03 Apr

Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
03 Apr

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

StockStory
·
03 Apr

BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients

Benzinga
·
03 Apr

BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents

MT Newswires Live
·
02 Apr

BRIEF-Biomarin Announces Positive Pivotal Data For Palynziq® (Pegvaliase-Pqpz) In Adolescents With Phenylketonuria

Reuters
·
02 Apr

Biomarin Pharmaceutical Inc - to Submit for Regulatory Approval Later This Year

THOMSON REUTERS
·
02 Apr

Biomarin Announces Positive Pivotal Data for Palynziq® (Pegvaliase-Pqpz) in Adolescents With Phenylketonuria

THOMSON REUTERS
·
02 Apr

US FDA approves Sanofi's bleeding disorder therapy

Reuters
·
29 Mar

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock

Zacks
·
28 Mar

2 Reasons to Like BMRN (and 1 Not So Much)

StockStory
·
26 Mar

Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

StockStory
·
24 Mar